Company Info

Levicept

Drug Discovery & Development

Overview

With more than 1 billion people worldwide living with some type of chronic pain, a large unmet medical need for safe and effective analgesics exists. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used drugs to treat pain and inflammation associated with osteoarthritis, but their use is limited by adverse effects on gastrointestinal and platelet function, as well as increased cardiovascular liability.

Levicept Ltd is an asset-centric UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. LEVI-04 is currently in phase I clinical trials investigating pharmacokinetics, safety and efficacy in osteoarthritis patients.

1 Contributions1 / 1

Biotech-CDMO Relationship

Illustrating a Successful Small Biotech-CDMO Relationship

Simon Westbrook, Ph.D.

Levicept

PAO-08-21-CL-03Aug 03, 2021

1 / 1

1 Contributors1 / 1

Simon Westbrook, Ph.D.

Founder and CEO

1 / 1